Using Xerava to prevent infections in patients with blood cancers and low white blood cell counts

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the use of Xerava™ (eravacycline) as a prophylactic antibiotic in patients with hematological malignancies undergoing chemotherapy or hematopoietic stem cell transplantation who are at risk of prolonged neutropenia. The study aims to assess the incidence of breakthrough infections during eravacycline prophylaxis in this vulnerable population. Eravacycline is chosen for its broad-spectrum activity against multi-drug resistant bacteria, making it a promising alternative for infection prevention. Participants will be monitored for adverse effects and the effectiveness of the treatment in reducing infection rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients receiving induction chemotherapy for treatment of acute leukemia or receiving preparative regimen for HSCT
* Patient must provide informed consent.
* Bilirubin ≤ 3 x the ULN and AST/ALT ≤ 5 x ULN

Exclusion Criteria:

* Uncontrolled bacterial, viral or fungal infection at the time of study enrollment.
* Urinary tract infection receiving active treatment
* Acute pancreatitis (not necessary to work-up unless symptomatic)
* History of known hypersensitivity to eravacycline, tetracycline, doxycycline, minocycline, tigecycline, sarecycline, oxytetracycline, or omadacycline
* Pseudomonas infection within 30 days prior to study enrollment
* Receiving strong inhibitors or inducers of cytochrome P450 3A4 will be excluded from the study (see Appendix B for complete list of medications)
* Pregnant or lactating women

Where it's running

• Aaron Cumpston
  Morgantown, West Virginia, United States Recruiting

Study contacts

• Principal investigator: Aaron Cumpston, PharmD, BCOP — West Virginia University
• Study coordinator: Aaron Cumpston, PharmD, BCOP
• Email: cumpstona@wvumedicine.org
• Phone: 3045984000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• G-CSF–fusion protein to prevent chemotherapy neutropenia in children with sarcoma

  This trial tests Albipagrastim alfa (QLC2519) in children with sarcoma to see if it helps prevent chemotherapy-induced neutropenia.

  Recruiting Phase 2 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07724756

• Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant

  This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07708987

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.